Is Phenibut Legal in Tennessee? (2026)

Instrument

Controlled substance analogue definition

Source

https://publications.tnsosfiles.com/acts/108/pub/pc0161.pdf

Retrieved

2026-11-06

Fingerprint

e7a081ab383479d6

(1) As used in this section, "controlled substance analogue" means a capsule,
        pill, powder, product or other substance, however constituted, that has the stimulant,
        depressant or hallucinogenic effect on the central nervous system of a controlled
        substance; and

                       (A) Has a chemical structure which is a derivative or structural analogue
               of the chemical structure of a controlled substance; provided, that as used in this
               subdivision, “analogue” means the structure of the tested item differs in no more
               than two (2) atoms, one (1) functional group, or one (1) double bond, from the
               structure of a controlled substance; or

                      (B) Is prohibited by § 39-17-452.

Instrument

Controlled substance analogue manufacture and distribution offense

Source

https://capitol.tn.gov/bills/107/Amend/HA1034.PDF

Retrieved

2026-11-01

Fingerprint

b192e6e04eaa3fa0

(c) It is an offense to knowingly manufacture, deliver, dispense or sell a controlled substance analogue or to possess a controlled substance analogue with the intent to manufacture, deliver, dispense or sell such substance.

Instrument

Offense: active chemical ingredient in salvia divinorum and synthetic cannabinoids

Source

https://publications.tnsosfiles.com/acts/108/pub/pc0161.pdf

Retrieved

2026-10-31

Fingerprint

1627aa378125b265

SECTION 1. Tennessee Code Annotated, Section 39-17-438, is amended by deleting
subsection (a) and substituting instead the following:

       (a)

               (1) It is an offense to knowingly produce, manufacture, distribute, possess or
       possess with intent to produce, manufacture or distribute the active chemical ingredient
       in the hallucinogenic plant salvia divinorum or the following synthetic cannabinoids:

                     (A) (6a, 1Oa)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2methyloctan-2-yl)-6a,
              7,10,10a-tetrahydrobenzo[c]chromen-1-ol; including, but not limited to HU 210 or
              HU 211;

                      (B) Naphthoylindoles being any compound structurally derived from 3-(1-
              naphthoyl) indole with substitution at the nitrogen atom· of the indole ring whether
              or not further substituted in the indole ring to any extent, whether or not
              substituted in the naphthyl ring to any extent; including, but not limited to JWH-
              015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210,
              AM-1220, MAM-2201 or AM-2201;

                       (C) Naphthylmethylindoles being any compound structurally derived from
              a 1 H-indole-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen
              atom of the indole ·ring whether or not further substituted in the indole ring to any
              extent, whether or not substituted in the naphthyl ring to any extent; including, but
              not limited to JWH-175, JWH-184 or JWH-199;

                      (D) Naphthoylpyrroles, being any compound structurally derived from 3-
              (1-naphthoyl) pyrrole with substitution at the nitrogen atom of the pyrrole ring
              whether or not further substituted in the pyrrole ring to any extent, whether or not
              substituted in the naphthyl ring to any extent; including, but not limited to JWH-
              307;

                     (E) Naphthylmethylindenes, being any compound structurally derived
              from 1-(1-naphthylmethyl) indene with substitution at the 3-position of the indene
              ring whether or not further substituted in the indene ring to any extent, whether or
              not substituted in the naphthyl ring to any extent; including, but not limited to
              JWH-176;

                      (F) Phenylacetylindoles, being any compound structurally derived from 3-
              phenylacetylindole with substitution at the nitrogen atom of the indole ring
              whether or not further substituted in the indole ring to any extent, whether or not
              substituted in the phenyl ring to any extent; including but.not limited to JWH-167,
              JWH-201, JWH-203, JWH-250, JWH-251, JWH-302 or RCS-8;
HB 12


                      (G) Cyclohexylphenols, being any compound structurally derived from 2-
               (3-hydroxycyclohexyl) phenol with substitution at the 5-position of the phenolic
               ring whether or not further substituted in the whether or not substituted in the
               cyclohexyl ring to any extent; including, but not limited to CP 47,497 or the
               dimethylhexyl, dimethyloctyl or dimethylnonyl homologues of CP 47,497;

                      (H) Tetrahydro derivatives of cannabinol and 3-alkyl homologues of
               cannabiniol or of its tetrahydro derivatives, except where contained in cannabis
               or cannabis resin;

                       (I) Benzoylindoles, being any compound containing a 3-(benzoyl) indole
               structure with substitution at the nitrogen atom of the indole ring whether or not
               further substituted in the indole ring to any extent and whether or not substituted
               in the phenyl ring to any extent; including, but not limited to AM-694, Pravadoline
               (WIN 48, 098), RCS-4, AM-1241 or AM-2233;

                       (J) WIN-55, 212-2 or 2, 3-Dihydro-5-methyl-3-(4 Morpholinylmethyl)
               pyrrolo [1 ,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenylmethanone;

                       (K) Cyclopropanoylindoles, being any compound structurally derived
               from a 3-(cyclopropylmethanoyl)indole structure with substitution at the nitrogen
               atom of the indole ring, whether or not further substituted in the indole ring to any
               extent and whether or not substituted in the cyclopropyl ring to any extent;
               including, but not limited to UR-144, XLR-11 or A-796,260;

                       (L) Adamantoylindoles, being any compound structurally derived from a
               3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the
               indole ring, whether or not further substituted in the indole ring to any extent and
               whether or not substituted in the adamantly ring to any extent; including, but not
               limited to AM-1248 or AB-001;

                       (M) Adamantoylindolecarboxamides, being any compound structurally
               derived from a N-adamantyl-1-indole-3-carboxamide with substitution at the
               nitrogen atom of the indole ring, whether or not further substituted in the indole
               ring to any extent and whether or not substituted in the adamantyl ring to any
               extent; including but not limited to STS-135, 2NE 1;

                       (N) Adamantylindazolecarboxamides, being any compound structurally
               derived from a N-adamantyl-1-indazole-3-carboxamide with substitution at the
               nitrogen atom of the indazole ring, whether or not further substituted in the
               indazole ring to any extent and whether or not substituted in the adamantly ring
               to any extent; including, but not limited to AKB-48; and

                       (0) Naphthoylnaphthalene, being any compound structurally derived
               from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either
               of the naphthalene rings to any extent; including, but not limited to CB-13.

               (2) Subdivision (a)(1) concerning synthetic cannabinoids shall not apply to drugs
        or substances lawfully prescribed or to drugs or substances which have been approved
        or approved for study by the federal food and drug administration.

Instrument

Controlled Substances in Schedule I, hallucinogenic substances

Source

https://publications.tnsosfiles.com/rules/0940/0940-06/0940-06-01.20251215.pdf

Retrieved

2026-11-06

Fingerprint

9ead35266367d549

(4)   Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule,
           any material, compound mixture, or preparation, which contains any quantity of the following
           hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers
           whenever the existence of such salts, isomers, and salts of isomers, is possible within the
           specified chemical designation (for purposes of this paragraph only, the term "isomer"
           includes the optical, position and geometric isomers):

           (a)   Alpha-ethyltryptamine  7249
                 Other names: etryptamine; Monase; [alpha]-ethyl-1H-indole-3-ethanamine; 3-(2-
                 aminobutyl) indole; [alpha]-ET; and AET; ET; Trip

           (b)   Alpha-methyltryptamine   7432
                 Other name: AMT

           (c)   Alpha-pyrrolidinobutiophenone  7546
                 Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one

           (d)   Alpha-pyrrolidinopentiophenone  7545



December, 2025 (Revised)                          8
CONTROLLED SUBSTANCES                                                           CHAPTER 0940-06-01

(Rule 0940-06-01-.01, continued)
                 Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-
                 yl)pentan-1-one

           (e)   4-Bromo-2,5-dimethoxyamphetamine  7391
                 Other names: 4-Bromo-2,5-dimethoxy-[alpha]-methylphenethylamine; 4-bromo-2,5-
                 DMA

           (f)   4-Bromo-2,5-dimethoxyphenethylamine  7392
                 Other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl
                 DOB; 2C-B; Nexus

           (g)   2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  7536
                 Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36

           (h)   Bufotenine  7433
                 Other names: 3-([beta]-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
                 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
                 dimethyltryptamine; mappine

           (i)   Butylone  7541
                 Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one

           (j)   2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  7537
                 Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82

           (k)   Diethyltryptamine  7434
                 Other names: N,N-Diethyltryptamine; DET

           (l)   2,5-Dimethoxyamphetamine  7396
                 Other names: 2,5-Dimethoxy-[alpha]-methylphenethylamine; 2,5-DMA

           (m)   2,5-Dimethoxy-4-ethylamphetamine  7399
                 Other name: DOET

           (n)   2,5 Dimethoxy-4-propylthiophenethylamine  7348
                 Other name: 2C-T-7

           (o)   Dimethyltryptamine  7435
                 Other name: DMT

           (p)   Ethylamine analogue of phencyclidine  7455
                 Other names: N-Ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine; N-(1-
                 phenylcyclohexyl)ethylamine; cyclohexamine; PCE

           (q)   2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one  7286
                 Other names: MXE; methoxetamine

           (r)   Ethylone  7547
                 Other names: 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one; 3,4-
                 methylenedioxy-N-ethylcathinone; bk-MDEA; MDEC

           (s)   Ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate  7094
                 Other names: 5F-EDMB-PICA; 5F-EDMB-2201

           (t)   Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate  7036
                 Other name: 5F-EDMB-PINACA



December, 2025 (Revised)                           9
CONTROLLED SUBSTANCES                                                           CHAPTER 0940-06-01

(Rule 0940-06-01-.01, continued)

           (u)    (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone  7014
                  Other name: FUB-144

           (v)    3-Fluoro-N-methylcathinone  1233
                  Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one

           (w)    4-Fluoro-N-methylcathinone  1238
                  Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one

           (x)    1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide   7083
                  Other names: 5F-CUMYL-PINACA, SGT-25

           (y)    Ibogaine  7260
                  Other names: 7-Ethyl-6,6[beta],7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-
                  pyrido [1’,2’:1,2] azepino [5,4-b] indole; Tabenanthe iboga.

           (z)    2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  7538
                  Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5

           (aa) Lysergic acid diethylamide  7315
                Other name: LSD

           (bb) Mescaline  7381
                Other name: Constituent of “Peyote” cacti

           (cc)   4-Methoxyamphetamine  7411
                  Other names: 4-methoxy-[alpha]-methylphenethylamine; paramethoxyamphetamine;
                  PMA

           (dd) 5-Methoxy-3,4-methylenedioxyamphetamine  7401

           (ee) 5-Methoxy-N,N-diisopropyltryptamine  7439
                Other name: 5-MeO-DIPT

           (ff)   5-methoxy-N,N-dimethyltryptamine   7431
                  Other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT

Instrument

Controlled substances in Schedule II

Source

https://publications.tnsosfiles.com/rules/0940/0940-06/0940-06-01.20251215.pdf

Retrieved

2026-11-01

Fingerprint

8e27c78f49686562

(8) 
Tianeptine and any salt, sulfate, free acid, or other preparation of tianeptine, and any salt, 
sulfate, free acid, compound, derivative, precursor, or other preparation thereof that is 
substantially chemically equivalent or identical with tianeptine.

Instrument

Controlled Substances in Schedule III: depressants

Source

https://publications.tnsosfiles.com/rules/0940/0940-06/0940-06-01.20230101.pdf

Retrieved

2026-10-31

Fingerprint

ce895d0c2e142997

(3)   Depressants. Unless specifically excepted or unless listed in another schedule, any material,
           compound, mixture, or preparation which contains any quantity of the following substances
           having a depressant effect in the central nervous system:

           (a)   Any compound, mixture, or preparation containing:

                 1.    Amobarbital 2126

                 2.    Secobarbital 2316

                 3.    Pentobarbital 2271
                       Or any salt thereof and one or more other active medicinal ingredients which are
                       not listed in any schedule.

           (b)   Any suppository dosage form containing:

                 1.    Amobarbital 2126

                 2.    Secobarbital 2316

                 3.    Pentobarbital 2271
                       Or any salt of these drugs and approved by the Food and Drug Administration for
                       marketing only as a suppository.

           (c)   Any substance which contains any quantity of a derivative of barbituric acid or any salt
                 thereof.
                 Examples include the following drugs: 2100

                 1.    Aprobarbital 2100

                 2.    Butabarbital (secbutabarbital) 2100

                 3.    Butalbital 2100

                 4.    Butobarbital (butethal) 2100

                 5.    Talbutal 2100

                 6.    Thiamylal 2100

                 7.    Thiopental 2100

                 8.    Vinbarbital 2100




January, 2023 (Revised)                           19
CONTROLLED SUBSTANCES                                                               CHAPTER 0940-06-01

(Rule 0940-06-01-.03, continued)
           (d)   Chlorhexadol 2510

           (e)   Embutramide 2020

           (f)   Gamma hydroxybutyric acid preparations. Any drug product containing gamma
                 hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an
                 application is approved under § 505 of the federal Food, Drug, and Cosmetic Act,
                 codified in 21 U.S.C. §§ 301, et seq 2012

           (g)   Ketamine, its salts, isomers, and salts of isomers 7285
                 Other name: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone

           (h)   Lysergic acid 7300

           (i)   Lysergic acid amide 7310

           (j)   Methyprylon 2575

           (k)   Perampanel, and its salts, isomers, and salts of isomers 2261

           (l)   Sulfondiethylmethane 2600

           (m)   Sulfonethylmethane 2605

           (n)   Sulfonmethane 2610

           (o)   Tiletamine and zolazepam or any salt of tiletamine or zolazepam 7295

                 1.    Other name for a tiletamine-zolazepam combination product: Telazol®.

                 2.    Other name for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

                 3.    Other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
                       trimethylpyrazolo[3,4-e],[1,4]-diazepin-7(1H)-one; flupyrazapon.

Instrument

Controlled Substances in Schedule VII

Source

https://publications.tnsosfiles.com/rules/0940/0940-06/0940-06-01.20230101.pdf

Retrieved

2026-10-31

Fingerprint

cc136d75af5e1809

0940-06-01-.07 CONTROLLED SUBSTANCES IN SCHEDULE VII.

      (1)   Butyl nitrite and any isomer of butyl nitrite.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403. Administrative
History: Original rule filed April 29, 1981; effective June 18, 1981. Repeal and new rule filed May 25,
1984; effective June 24, 1984. Repeal and new rule filed September 6, 1985; effective October 10, 1985.
Repeal and new rule filed December 17, 1986; effective January 31, 1987. Repeal and new rule filed
January 7, 2011; effective April 7, 2011. Repeal and new rule filed December 20, 2013; effective March
20, 2014. Repeal and new rule filed February 24, 2015; effective May 25, 2015. Repeal and new rule filed
March 4, 2016; effective June 2, 2016. Repeal and new rules filed March 21, 2017; effective June 19,
2017. Repeal and new rules filed July 5, 2018; effective October 3, 2018.